In particular, the use of abatacept either by itself or in combination with Ruxolitinib (mAb targeting IFN-γ/JAK2/STAT1 signaling pathway) has led to a notable decrease in mortality among patients suffering from ICI-associated myocarditis and myositis (165). The gene discussed is IFNG; the disease is myocarditis.